RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SINIGAGLIA L
Collezione AOU Città della Salute di Torino

Items : 6

Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study. in Clinical and experimental rheumatology / Clin Exp Rheumatol. 2021 Mar-Apr;39(2):263-268. doi: 10.55563/clinexprheumatol/q69z52. Epub 2020 Jun

2021
AOU Alessandria
AO Ordine Mauriziano
AOU Città della Salute di Torino

Stobbione P; Sinigaglia L; Capri S; Sarzi-Puttini P; Fusaro E; Gorla R; Lomater C; Manara M; Caporali R; Manara M; Caporali R; Lomater C; Gorla R; Fusaro E; Sarzi-Puttini P; Stobbione P; Capri S; Sinigaglia L;

Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. in Minerva medica / Minerva Med. 2021 Apr;112(2):246-254. doi: 10.23736/S0026-4806.21.06902-0. Epub 2021 Feb 8.

2021
ASL Vercelli
AOU Città della Salute di Torino

Sinigaglia L; Bianchi G; Santilli D; Saviola G; Rossini M; Romano C; Govoni M; Magnani L; Manzo C; Giusti A; Azzolini V; Bellintani C; Belloli L; Belai Beyene N; Bucci R; Caporali R; Cappelli A; Corbelli V; DE Gennaro F; Fusaro E; Allara R; Serban T;

COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). in Clinical and experimental rheumatology / Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28.

2020
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Sinigaglia L; Gerli R; Sebastiani GD; Caporali R; Alunno A; Andreoli L; Carrara G; Zanetti A; Landolfi G; Chighizola C; Scirè CA; Valesini G;

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. in Journal of clinical medicine / J Clin Med. 2019 Nov 18;8(11):2013. doi: 10.3390/jcm8112013.

2019
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Castañeda S; Selva-O'Callaghan A; Matucci-Cerinic M; Triantafyllias K; Lopez-Mejias R; Vicente E; Zampogna G; Gonzalez Perez MI; Mejia M; Bellando Randone S; Gerli R; Bartoloni E; Quartuccio L; Fornaro M; Franceschini F; Iannone F; Schett G; Knitza J; Distler J; Claudia L; Pozzi MR; Dei G; Pesci A; Locatelli F; Marchioni E; Caporali R; Cifrian J; Salaffi F; Giorgi R; et alii...

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. in International journal of rheumatic diseases / Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30.

2018
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pellerito R; Sarzi Puttini PC; Fusaro E; Atzeni F; Bazzani C; Grosso V; Gorla R; Becciolini A; Caporali R; Sinigaglia L; Favalli EG;

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. in Clinical and experimental rheumatology / Clin Exp Rheumatol. 2017 Sep-Oct;35(5):804-809. Epub 2017 Jul 27.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pellerito R; Fusaro E; Bazzani C; Gorla R; Sarzi Puttini P; Atzeni F; Grosso V; Favalli EG; Caporali R; Manara M; Rocchetta PA; Sinigaglia L;